A panel of expert advisers to the U.S. Food and Drug Administration on Friday voted in favor of authorizing Johnson & Johnson’s one-dose COVID-19 vaccine for emergency use, bringing it an important step closer to a U.S. rollout.
The FDA is likely to authorize the vaccine for emergency use within a day or so, making it the third available in the United States, and the only one that requires a single shot.
The panel consisting of doctors, infectious disease experts and medical researchers voted unanimously that the benefits of the vaccine outweigh its risks in people age 18 and over.
J&J has said it will be able to ship three million to four million doses of …
Keep on reading: Advisory panel unanimously recommends FDA authorize Johnson & Johnson COVID-19 vaccine